SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently facing intense selling pressure as it hits new 52-week lows, driven by a combination of sentiment shifts, sector-wide software weakness, and concerns over contract competition in Europe. While some investors view the price drop as a value opportunity given the company's strong government and enterprise growth metrics, the community is deeply divided between those defending the long-term fundamentals and others bracing for further downside toward deeper support levels.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing a highly polarized trading environment as investors weigh the stock's massive parabolic gains against significant skepticism regarding its cyclical fundamentals and valuation. The community remains deeply divided, with bulls pointing to sustained memory supply shortages to justify the momentum, while bears are aggressively betting on a sharp reversal due to extreme technical overextension.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense bullish momentum driven by a strategic AI infrastructure agreement with Anthropic and heavy institutional positioning ahead of upcoming earnings. While the community is debating whether the stock is undergoing a structural re-rating or forming an unsustainable bubble, many are highlighting high call volume and the critical role of memory in AI data centers as key catalysts for its recent rally.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Investors are currently navigating a divergence between broad technology sector weakness, with several major names hitting 52-week lows, and the persistent strength of semiconductor and memory stocks propping up the indices. Market participants are actively debating whether this sector rotation signals a broader liquidity crunch and sustainable AI growth concerns or merely temporary consolidation ahead of upcoming inflation data.

Roundhill ETF Trust - Roundhill Memory ETF

Roundhill Memory ETF ($DRAM) is trending as investors aggressively rotate capital into AI infrastructure, specifically focusing on memory chip bottlenecks like high-bandwidth memory (HBM). Community sentiment is heavily bullish, with many participants citing the potential for sector re-rating due to long-term supply contracts and the stock's role as a concentrated proxy for industry leaders like Micron and SK Hynix.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is facing intense scrutiny as a high-conviction target for both deep-value investors anticipating a potential buyout and short sellers betting on structural operational headwinds. The community is sharply divided, balancing bullish sentiment driven by the company's dividend yield, international expansion, and new leadership against frustration over stagnant price action and service quality.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is currently trending as investors monitor an executive order from the White House that highlights quantum sensing and networking as a national priority. The community is actively discussing the company's participation alongside industry giants, with many traders speculating on the potential for government-backed growth and the upcoming webinar on neutral-atom quantum computing advancements.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is facing intense volatility as the market digests its massive valuation and recent debt issuance, fueling a fierce debate between retail investors bracing for a potential further drop and those holding for long-term growth. The stock is currently being driven by heavy speculation surrounding upcoming share lockup expirations, aggressive institutional buying, and deep skepticism regarding the company's path to profitability amidst its pivot to AI infrastructure.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending as investors digest news of a multi-billion dollar acquisition aimed at deepening its immunology pipeline, which some community members view as a strategic move to secure long-term growth. Meanwhile, sentiment remains split, with some traders focused on the potential competitive impact of the deal, while others continue to debate the broader biotech sector's M&A activity and the company's long-term product efficacy.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF (DIA) is trending as investors grapple with extreme risk-on sentiment and concerns over a late-cycle market bubble amid ongoing semiconductor cycle volatility. Community members are actively debating the sustainability of current AI-driven momentum, with many highlighting the risks posed by potential interest rate hikes and broader geopolitical instability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leader, to the Ionis Board of Directors, effective immediately.We are pleased to welcome Dr. Hantson to the board, said Joseph Loscalzo, M.D., Ph.D...

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag

Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) will be presented during four oral presentations at upcoming medical conferences. Data will be presented...

Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). Results from the two Phase 3 trials, B-Well 1 and B-Well 2, were simultaneously published...

BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal

Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimers disease

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating diranersen (IONIS-MAPTRx/BIIB080), an...

Tweedy Browne Co LLC Decreases Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS

Tweedy Browne Co LLC lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 15.0% during the fourth quarter, according to the company in its most recent filing with...

Ionis to host 2026 virtual Annual Meeting of Stockholders

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4...

What is HC Wainwright's Estimate for IONS Q1 Earnings?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Ionis Pharmaceuticals in a report released on Thursday, April 30th. HC Wainwright analyst M. Kapoor anticipates that the company will post earni...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Ionis Pharmaceuticals Inc

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$75.89
Prev Close	$74.12
Open	$74.85
Dividend Yield	0.00%
50-Day Moving Average	$74.88
Beta	0.71
Avg. Volume	1.67M
PE Ratio	-36.10

52-Week High	$86.74
52-Week Low	$37.32
Market Capitalization	$12.25B
EPS (Annual)	-$2.38
Price to Book	25.62
Revenue Per Employee	$673,117.69

Feed

News

Sentiment

Earnings

Fundamentals

Info

IONSIonis Pharmaceuticals Inc

Latest IONS News